The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients

British Journal of Haematology

Volumn 118, Issue 1, 2002, Pages 330-336

  Ceci, Adriana ^a,l   Baiardi, Paola ^b   Felisi, Mariagrazia ^a   Cappellini, Maria Domenica ^c   Carnelli, Vittorio ^d   De Sanctis, Vincenzo ^e   Galanello, Renzo ^f   Maggio, Aurelio ^g   Masera, Giuseppe ^d   Piga, Antonio ^h   Schettini, Francesco ⁱ   Stefàno, Ippazio ^j   Tricta, Fernando ^k  

^a UNIVERSITY OF BARI   (Italy)

^b IRCCS   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^f Ist Clin Biol dell'Eta Evolutiva   (Italy)

^g VILLA SOFIA CERVELLO HOSPITAL   (Italy)

^h UNIVERSITY OF TURIN   (Italy)

ⁱ Dipartimento di Biomedicina dell'Eta Evolutiva   (Italy)

^j Azienda Ospedaliera Taranto   (Italy)

^k Apotex Research Inc   (Canada)

^l Department of Biostatistics   (Italy)

more..

Author keywords

Chelation therapy; Deferiprone; Effectiveness; Safety; Thalassaemia major

Indexed keywords

ALANINE AMINOTRANSFERASE; DEFERIPRONE;

ADOLESCENT; ADULT; AGRANULOCYTOSIS; ARTHRALGIA; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FERRITIN BLOOD LEVEL; GASTROINTESTINAL DISEASE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; SPLENECTOMY; THALASSEMIA;

ADOLESCENT; ADULT; AGRANULOCYTOSIS; ALANINE TRANSAMINASE; BETA-THALASSEMIA; BLOOD TRANSFUSION; CHILD; COHORT STUDIES; DRUG MONITORING; FEMALE; FERRITINS; HUMANS; IRON CHELATING AGENTS; ITALY; MALE; MIDDLE AGED; NEUTROPENIA; PYRIDONES; SPLENECTOMY;

EID: 0036068230     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2002.03554.x     Document Type: Article

References (27)

1. Meta-analytic review of the clinical effectiveness of oral deferiprone (L1)
2. Long term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial
3. Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major
4. Deferiprone associated myelotoxicity
5. Results of long-term deferiprone (L1) therapy. A report by the International Study Group on Oral Iron Chelators
6. The Sydney Children's Hospital experience with the oral iron chelator deferiprone (L1)
7. Arthropathy in thalassemia patients receiving deferiprone
8. Iron chelation with oral deferiprone in patients with thalassemia
9. Safety profile of the oral iron chelator deferiprone: A multicentre study
10. Factors influencing effectiveness of deferiprone in a thalassemia major clinical setting
11. Treatment of Cooley's anemia
12. Iron chelators for thalassaemia
13. Oral iron chelation
14. Long term trial of deferiprone in 51 transfusion-dependent iron overloaded patients
15. Good practice in the postmarketing surveillance of medicines
16. Oral iron chelating therapy. A single center interim report on deferiprone (L1) in thalassemia
17. Long-term therapy with deferiprone
18. Iron-chelating therapy and the treatment of thalassemia
19. Iron-chelation therapy with oral deferiprone in patients with thalassemia major
20. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major
21. No progression of liver fibrosis in thalassemia major during deferiprone or desferrioxomine iron chelation
22. A risk-benefit assessment of iron-chelation therapy
23. Iron chelation with deferiprone in patients with thalassemia
24. Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients
25. Absence of deferiprone-induced hepatic fibrosis: A multi-center study